The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ViroPharma's revenues will expand 10.7% and EPS will increase 44.4%.
The average estimate for revenue is $104.8 million. On the bottom line, the average EPS estimate is $0.13.
Last quarter, ViroPharma reported revenue of $107.1 million. GAAP reported sales were 21% lower than the prior-year quarter's $135.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.15. GAAP EPS were -$0.98 for Q1 versus $0.26 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 72.1%, 430 basis points worse than the prior-year quarter. Operating margin was 6.4%, much worse than the prior-year quarter. Net margin was -59.7%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $449.1 million. The average EPS estimate is $0.71.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 1,181 members out of 1,219 rating the stock outperform, and 38 members rating it underperform. Among 326 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 323 give ViroPharma a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ViroPharma is outperform, with an average price target of $33.67.
- Add ViroPharma to My Watchlist.